Kezar Life Sciences has become the latest biotech to decide that it could do better than a buyout offer from Concentra Biosciences. Concentra’s parent company Tang Capital Partners has a track ...
(RTTNews) - Kezar Life Sciences (KZR) announced that its Board has rejected the unsolicited, non-binding proposal from Concentra Biosciences, to acquire all of the outstanding shares of common ...
Earlier on Thursday, Kezar Life Sciences rejected the previously disclosed unsolicited, non-binding proposal from Concentra Biosciences for cash consideration of $1.10 per share, plus a contingent ...
1 Day CON 0.52% DJIA 0.09% S&P Mid Cap 400 0.01% Health Care/Life Sciences 0.22% ...
1 Day CON -2.54% DJIA 0.37% S&P Mid Cap 400 0.15% Health Care/Life Sciences -0.15% ...
Thank you for reporting this station. We will review the data in question. You are about to report this weather station for bad data. Please select the information that is incorrect.
After hours: October 18 at 4:06 PM EDT Loading Chart for MD ...
Thank you for reporting this station. We will review the data in question. You are about to report this weather station for bad data. Please select the information that is incorrect.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback